CD4 and tuberculosis: The Statens Serum Institut Hybrid (H1) recombinant fusion protein (antigen (Ag)85B- Early Secretory Antigenic Target (ESAT)-6) TB vaccine, adjuvanted with IC31, has been shown to be safe and immunogenic in BCG unvaccinated, TB uninfected participants and in BCG vaccinated and latently TB infected participants [4] In this phase II trial we evaluated the safety and immunogenicity of H1/IC31administered to HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3 and without evidence of active TB disease (PACTR Identifier: PACTR201105000289276).